Her primary scientific interests are in Cancer research, Apoptosis, Cisplatin, Drug resistance and Cell culture. Her Cancer research study integrates concerns from other disciplines, such as Cytotoxic T cell, Lung cancer, Immunology and Cytotoxicity. The study incorporates disciplines such as Tumor suppressor gene, Tumor progression and DNA damage in addition to Apoptosis.
The various areas that she examines in her Cisplatin study include Ovarian carcinoma, Ovarian cancer, Oxaliplatin and Platinum Compound. Her research integrates issues of Camptothecin and Tumour heterogeneity in her study of Drug resistance. Her studies deal with areas such as Endocrinology and Internal medicine as well as Cell culture.
Paola Perego mainly investigates Cancer research, Cisplatin, Apoptosis, Cell culture and Pharmacology. Her Cancer research research incorporates themes from Cell, Cancer, Internal medicine, Immunology and Cytotoxicity. Her Cisplatin research is multidisciplinary, incorporating elements of Osteosarcoma, Ovarian carcinoma, Ovarian cancer, Oxaliplatin and Molecular biology.
Her Apoptosis research includes elements of Tumor suppressor gene, Cytotoxic T cell, DNA damage and In vivo. Her Cell culture research is multidisciplinary, incorporating perspectives in Caspase 3, A431 cells, Biochemistry and Melanoma. Paola Perego combines subjects such as Camptothecin, Cancer cell, Topotecan, Topoisomerase and Drug resistance with her study of Pharmacology.
Her primary areas of investigation include Cancer research, Pharmacology, Apoptosis, Cisplatin and Cancer. She interconnects Cell, Cell growth, Tyrosine-kinase inhibitor, Cytotoxic T cell and In vivo in the investigation of issues within Cancer research. Her biological study spans a wide range of topics, including Cell culture, DNA damage, Ovarian carcinoma, Receptor and Drug resistance.
Her Apoptosis study combines topics in areas such as Drug interaction, microRNA and Transcription factor. Paola Perego has included themes like Lung cancer, Oxaliplatin and DNA repair in her Cisplatin study. Her study looks at the relationship between DNA repair and topics such as Topoisomerase, which overlap with Molecular biology.
Paola Perego spends much of her time researching Cancer research, Cell growth, Pharmacology, Drug resistance and Cisplatin. With her scientific publications, her incorporates both Cancer research and Peptidomimetic. Her research investigates the connection with Cell growth and areas like Cancer cell which intersect with concerns in Intracellular, Biochemistry and Antioxidant.
Her Pharmacology research focuses on DNA damage and how it relates to PKC alpha, Transfection, Ovarian carcinoma, microRNA and Apoptosis. Her Drug resistance study combines topics from a wide range of disciplines, such as Tumor microenvironment, Immune system, Programmed cell death, Platinum Compound and Mitochondrion. Her work carried out in the field of Cisplatin brings together such families of science as FOXO1, Transcription factor, Oxaliplatin and DNA repair.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Giulia Bertolini;Luca Roz;Paola Perego;Monica Tortoreto.
Proceedings of the National Academy of Sciences of the United States of America (2009)
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
Giovanna Andreola;Licia Rivoltini;Chiara Castelli;Veronica Huber.
Journal of Experimental Medicine (2002)
Association between Cisplatin Resistance and Mutation of p53 Gene and Reduced Bax Expression in Ovarian Carcinoma Cell Systems
Paola Perego;Monica Giarola;Sabina C. Righetti;Rosanna Supino.
Cancer Research (1996)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Pádraig D'Arcy;Slavica Brnjic;Maria Hägg Olofsson;Mårten Fryknäs.
Nature Medicine (2011)
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.
N. Zaffaroni;M. Pennati;G. Colella;P. Perego.
Cellular and Molecular Life Sciences (2002)
A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Paola Perego;Claudia Caserini;Laura Gatti;Nives Carenini.
Molecular Pharmacology (1999)
A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.
Annalisa Castagna;Paolo Antonioli;Hubert Astner;Malimoud Hamdan.
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
Simona Romanelli;Paola Perego;Graziella Pratesi;Nives Carenini.
Cancer Chemotherapy and Pharmacology (1998)
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
Cinzia Lavarino;Silvana Pilotti;Maria Oggionni;Laura Gatti.
Journal of Clinical Oncology (2000)
A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts
G Pratesi;P Perego;D Polizzi;S C Righetti.
British Journal of Cancer (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: